CHAC1: A Potential Drug Target and Biomarker (G79094)

Target Name: CHAC1

NCBI ID: G79094

CHAC1

CHAC1: A Potential Drug Target and Biomarker

CHAC1 (CHAC1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, lungs, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. CHAC1 is unique due to its ability to interact with various signaling molecules, including TGF-β1, which is a key regulator of cell growth and differentiation.

The search for new drug targets and biomarkers is a critical aspect of modern medicine. Drug resistance is a major problem in healthcare, and the development of new treatments is necessary to improve outcomes. One approach to identify new drug targets is to use protein databases, such as the Protein Data Bank (PDB), to identify proteins that are involved in various cellular processes. In this article, we will discuss CHAC1 as a potential drug target and biomarker.

CHAC1 as a drug target

CHAC1 has been identified as a potential drug target due to its involvement in various cellular processes. One of the key functions of CHAC1 is its role in cell signaling. CHAC1 can interact with TGF-β1, which is a key regulator of cell growth and differentiation. This interaction between CHAC1 and TGF-β1 suggests that CHAC1 may be a useful target for drugs that are designed to modulate cell signaling.

In addition to its role in cell signaling, CHAC1 is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. CHAC1 is involved in the regulation of cell adhesion by interacting with various adhesion molecules, including cadherins and immunoglobulin-like cell adhesion molecules (Ig-CAMs). This suggests that CHAC1 may be a useful target for drugs that are designed to modulate cell adhesion.

CHAC1 as a biomarker

In addition to its potential as a drug target, CHAC1 is also a potential biomarker. The use of biomarkers is a promising approach to diagnostic and therapeutic decision making. CHAC1 has been identified as a potential biomarker for a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

One of the key advantages of using CHAC1 as a biomarker is its ability to be expressed in various tissues of the body, including cancer cells. This makes it a potential target for cancer therapies that target specific processes within cancer cells. In addition, CHAC1 has been shown to be involved in the regulation of cellular processes that are important in the development and progression of various diseases, including cancer. This suggests that CHAC1 may be a useful biomarker for diseases that are associated with altered cellular processes.

Conclusion

In conclusion, CHAC1 is a protein that is expressed in various tissues of the human body and is involved in various cellular processes. Its ability to interact with TGF-β1 and regulate cell signaling and adhesion suggests that it may be a useful drug target and biomarker. Further research is needed to determine the full range of functions of CHAC1 and its potential as a drug target and biomarker.

Protein Name: ChaC Glutathione Specific Gamma-glutamylcyclotransferase 1

Functions: Catalyzes the cleavage of glutathione into 5-oxo-L-proline and a Cys-Gly dipeptide. Acts specifically on glutathione, but not on other gamma-glutamyl peptides (PubMed:27913623). Glutathione depletion is an important factor for apoptosis initiation and execution. Acts as a pro-apoptotic component of the unfolded protein response pathway by mediating the pro-apoptotic effects of the ATF4-ATF3-DDIT3/CHOP cascade (PubMed:19109178). Negative regulator of Notch signaling pathway involved in embryonic neurogenesis: acts by inhibiting Notch cleavage by furin, maintaining Notch in an immature inactive form, thereby promoting neurogenesis in embryos (PubMed:22445366)

The "CHAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets